OCGN

Ocugen (OCGN)

Ocugen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OCGN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/29	20 : 15	GlobeNewswire Inc.	Ocugen to Present at BIO International Convention 2024	NASDAQ:OCGN	Ocugen Inc
2024/05/29	05 : 05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:OCGN	Ocugen Inc
2024/05/28	20 : 02	GlobeNewswire Inc.	Ocugen Set to Join Russell 3000® Index Effective June 28, 2024	NASDAQ:OCGN	Ocugen Inc
2024/05/20	20 : 00	GlobeNewswire Inc.	Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024	NASDAQ:OCGN	Ocugen Inc
2024/05/18	05 : 30	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:OCGN	Ocugen Inc
2024/05/15	19 : 30	GlobeNewswire Inc.	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy	NASDAQ:OCGN	Ocugen Inc
2024/05/15	04 : 54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCGN	Ocugen Inc
2024/05/14	21 : 00	GlobeNewswire Inc.	Ocugen Provides Business Update with First Quarter 2024 Financial Results	NASDAQ:OCGN	Ocugen Inc
2024/05/14	20 : 18	IH Market News	US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report	NASDAQ:OCGN	Ocugen Inc
2024/05/14	19 : 32	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:OCGN	Ocugen Inc
2024/05/11	05 : 15	Edgar (US Regulatory)	Form 8-A12G - Registration of securities [Section 12(g)]	NASDAQ:OCGN	Ocugen Inc
2024/05/11	05 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OCGN	Ocugen Inc
2024/05/11	05 : 05	GlobeNewswire Inc.	Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock	NASDAQ:OCGN	Ocugen Inc
2024/05/10	20 : 45	GlobeNewswire Inc.	Ocugen to Present at May 2024 Investor Conferences	NASDAQ:OCGN	Ocugen Inc
2024/05/03	20 : 30	GlobeNewswire Inc.	Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results	NASDAQ:OCGN	Ocugen Inc
2024/05/02	20 : 15	GlobeNewswire Inc.	Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress	NASDAQ:OCGN	Ocugen Inc
2024/04/29	19 : 45	GlobeNewswire Inc.	Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024	NASDAQ:OCGN	Ocugen Inc
2024/04/26	22 : 05	GlobeNewswire Inc.	UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting	NASDAQ:OCGN	Ocugen Inc
2024/04/26	19 : 30	GlobeNewswire Inc.	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting	NASDAQ:OCGN	Ocugen Inc
2024/04/19	20 : 13	GlobeNewswire Inc.	Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy	NASDAQ:OCGN	Ocugen Inc
2024/04/12	20 : 30	GlobeNewswire Inc.	Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets	NASDAQ:OCGN	Ocugen Inc
2024/04/10	20 : 02	GlobeNewswire Inc.	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	NASDAQ:OCGN	Ocugen Inc
2024/04/08	19 : 30	GlobeNewswire Inc.	Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication	NASDAQ:OCGN	Ocugen Inc
2024/04/05	20 : 02	GlobeNewswire Inc.	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy	NASDAQ:OCGN	Ocugen Inc
2024/04/02	21 : 00	GlobeNewswire Inc.	Ocugen Provides Business Update with Certain Financials for the Year Ending 2023	NASDAQ:OCGN	Ocugen Inc
2024/04/02	07 : 08	GlobeNewswire Inc.	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease	NASDAQ:OCGN	Ocugen Inc
2024/04/02	06 : 43	GlobeNewswire Inc.	Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023	NASDAQ:OCGN	Ocugen Inc
2024/03/18	19 : 30	GlobeNewswire Inc.	Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer	NASDAQ:OCGN	Ocugen Inc
2024/03/13	21 : 00	GlobeNewswire Inc.	Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410	NASDAQ:OCGN	Ocugen Inc
2024/03/06	21 : 30	GlobeNewswire Inc.	Ocugen to Present at Investing in Cures Summit	NASDAQ:OCGN	Ocugen Inc